Dermatology

Plaque Psoriasis Conference Series

Advertisement

The Role of GLP-1 Receptor Agonists in the Treatment of Patients With Plaque Psoriasis

conference reporter by Tina Bhutani, MD, MAS, FAAD
Overview

The current understanding of psoriasis as an immunometabolic disorder is beginning to impact the management of the disease. Under the guidance of multidisciplinary care teams, GLP-1 receptor agonists are emerging as a promising adjunctive strategy in the treatment of patients with plaque psoriasis. Several presenters at the 2026 Fall Clinical Dermatology Conference reviewed clinical trial findings and the real-world use of GLP-1 receptor agonists in patients with plaque psoriasis.

 

Following these presentations, featured expert Tina Bhutani, MD, MAS, FAAD, was interviewed by Conference Reporter Associate Editor-in-Chief Rick Davis, MS, RPh. Clinical perspectives from Dr Bhutani on these findings are presented here.

Expert Commentary
“The hope is that, when considering GLP-1 receptor agonist therapy for patients with obesity, in addition to improving their weight loss, we can also help them manage their cardiovascular disease, make their psoriasis easier to treat, and get them closer to the quality of life they deserve.”
— Tina Bhutani, MD, MAS, FAAD

This is a very exciting time for our patients with plaque psoriasis because, with the advent of GLP-1 receptor agonist therapy, we are learning a lot more about the disease process itself. During a session at the 2026 Fall Clinical Dermatology Conference, Mark Lebwohl, MD, and I discussed the importance of recognizing psoriasis as an immunometabolic disease. We have known for a long time that there is a bidirectional relationship between psoriasis and obesity. Patients with psoriasis tend to be overweight or obese, and those who are overweight or obese tend to develop psoriasis. We do not know exactly which comes first, but shared genetic factors may predispose patients to both conditions.

 

Moreover, we know that weight management is important for patients with psoriasis. Studies have shown that individuals with obesity are less likely to respond to treatment and that losing weight can improve treatment response. Until recently, our best options for losing weight were diet, exercise, and physical activity, which can be very hard to do. This can be especially challenging for patients with concomitant psoriatic arthritis, who may have increased difficulty moving and being physically active. Bariatric surgery was another option, but this is obviously more invasive.

 

As discussed during a multispecialty roundtable chaired by Joel M. Gelfand, MD, MSCE, FAAD, at this year’s Fall Clinical Dermatology Conference, GLP-1 receptor agonists can provide an option to help fill that gap without relying solely on diet and exercise, although we know that the combination works better. The hope is that, when considering GLP-1 receptor agonist therapy for patients with obesity, in addition to improving their weight loss, we can also help them manage their cardiovascular disease, make their psoriasis easier to treat, and get them closer to the quality of life they deserve.

 

The TOGETHER-PsO and TOGETHER-PsA trials provide objective data supporting this approach. Both trials compared ixekizumab alone with ixekizumab plus tirzepatide in either patients with psoriasis and overweight or obesity (TOGETHER-PsO) or patients with psoriatic arthritis and overweight or obesity (TOGETHER-PsA). In both trials, significantly more individuals receiving the combination treatment reached their desired end points than those treated with ixekizumab alone. These patients also lost at least 10% of their body weight. The thought had been that GLP-1 receptor agonists could potentially help in patients with psoriasis and obesity, but TOGETHER-PsO and TOGETHER-PsA provided us with objective data.

 

The question is: How do we have these conversations in our clinics? It can be off-putting to tell a patient that they need to lose weight, especially when the recommendation is coming from their dermatologist. I introduce the topic by explaining that plaque psoriasis is associated with cardiometabolic diseases, including heart attack, stroke, high cholesterol, and high blood pressure, and that losing weight may help reduce the risk of these comorbidities. In addition, for patients struggling to control their plaque psoriasis, reducing metabolically active adipose tissue may also decrease inflammation and make the disease easier to treat.

 

If dermatologists are uncomfortable initiating GLP-1 receptor agonists for appropriate patients, they can involve patients’ primary care providers, share the emerging data, and help coordinate multidisciplinary treatment. A multidisciplinary approach is important. I have been surprised by how receptive patients are to these discussions. Oftentimes, there is actually a sigh of relief from the patient, as many patients may have wanted to try these therapies but did not know how to access them or felt uncomfortable asking because of the stigma surrounding their use. They are often relieved to discuss these medications in the context of their overall health.

 

Another important question is: Do GLP-1 receptor agonists impact the efficacy and safety of oral plaque psoriasis therapies? Because GLP-1 receptor agonists slow gastric emptying, there have been questions about whether they might affect the absorption or passage of oral agents through the gastrointestinal system. A poster by Linda F. Stein Gold, MD, and colleagues presented at the 2026 Fall Clinical Dermatology Conference provided data for a subset of patients with moderate to severe plaque psoriasis from the initial icotrokinra phase 3 clinical trials who were also taking GLP-1–based medications. Dr Stein Gold et al showed that the use of these medications did not appear to influence the efficacy or safety of icotrokinra in this small subset.

 

GLP-1 receptor agonists have definitely entered the conversation on optimizing overall care for patients with plaque psoriasis. For those with overweight or obesity or those who have other cardiometabolic risk factors, we should be having these discussions and working with other clinicians involved in their care. We should think of GLP-1 receptor agonists as a potential adjunctive strategy in the treatment of patients with plaque psoriasis. We do not have data supporting their use alone to treat plaque psoriasis, but they can be an appropriate add-on therapy alongside existing plaque psoriasis treatments for appropriate patients.

References

Bhutani T, Lebwohl M. Transforming the care of psoriatic disease: recognizing psoriasis as an immunometabolic disease. Session presented at: 2026 Fall Clinical Dermatology Conference; October 8-11, 2026; Las Vegas, NV.

 

Biondi F, Veneziano G, Guida S, Rongioletti F. The metabolic-dermatologic axis: GLP-1/GIP agonists as emerging immunometabolic therapies for obesity-associated skin disease. Clin Dermatol. Published online October 12, 2026. doi:10.1016/j.clindermatol.2026.09.040

 

Gelfand JM, Fitch A, Lee J, Nelson W, Yu H. Bridging perspectives: a multispecialty roundtable on GLP-1 receptor agonists in psoriasis. Session presented at: 2026 Fall Clinical Dermatology Conference; October 8-11, 2026; Las Vegas, NV.

 

Lebwohl M, Blauvelt A, Kartman CE, et al. Ixekizumab with or without tirzepatide in adults with psoriasis and overweight or obesity: a phase 3b randomized clinical trial. JAMA Dermatol. 2026;162(7):709-719. Published correction appears in JAMA Dermatol. 2026;162(7):759.

 

Merola JF, Mease P, Kivitz A, et al. Ixekizumab with tirzepatide achieved greater disease control than ixekizumab alone in adults with psoriatic arthritis and overweight or obesity: results from a randomized clinical trial. Arthritis Rheumatol. 2026;78(10):2089-2101. doi:10.1002/art.70134

 

Nicolau J, López-Ferrer A, de la Cueva P. Management of obesity in psoriasis consultations. Dermatol Ther (Heidelb). 2026;16(2):687-700. doi:10.1007/s13555-026-01664-7

 

Stein Gold L, Armstrong AW, Soung J, et al. Effects of glucagon-like peptide-1 (GLP-1)–based medications on icotrokinra efficacy, safety, and pharmacokinetics: pooled results across ICONIC phase 3 studies. Poster presented at: 2026 Fall Clinical Dermatology Conference; October 8-11, 2026; Las Vegas, NV.

 

This information is brought to you by Engage Health Media and is not sponsored, endorsed, or accredited by the 2026 Fall Clinical Dermatology Conference.

Tina Bhutani, MD, MAS, FAAD

CEO, Synergy Dermatology
Associate Clinical Professor
Department of Dermatology
University of California, San Francisco
San Francisco, CA

Advertisement